<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03373266</url>
  </required_header>
  <id_info>
    <org_study_id>IRB0000871242</org_study_id>
    <nct_id>NCT03373266</nct_id>
  </id_info>
  <brief_title>Serun Fluoride and Kidney Transplant</brief_title>
  <official_title>Implication of Serum Fluoride Level Caused by Sevoflurane Versus Isoflurane Anesthesia Upon Renal Function After Kidney Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our primary goal is to investigate any hidden burden upon the grafted kidney from the
      increase of serum fluoride resulted from sevoflurane, versus isoflurane.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eighty patients with end stage renal failure undergoing living donor kidney transplant under
      general anesthesia were included in this study, by using an open (non-blinded) study design,
      patients were randomly assigned to two groups, 15 patients in each. Randomization was done
      through computer generated random tables. Isoflurane group; anesthesia was maintained with
      isoflurane 1-2%. Sevoflurane group; anesthesia was maintained with Sevoflurane 1-2%.

      A peripheral intravenous access was secured in the hand opposite to the functioning fistula
      and induction of anesthesia was done with propofol 2mg/kg, neuromuscular blockade was
      maintained with atracurium 0.6mg/kg and all patients were intubated and ventilated to
      maintain end-tidal carbon dioxide (ETCO2) concentration between 30-40 mmHg. Anaesthesia was
      maintained with 1-2% isoflurane (isoflurane group) or 1-2% sevoflurane (sevoflurane group)
      with fresh gas flow of 2 L/min. In both groups inhalational anesthetic was delivered in an
      air-oxygen mixture of 1:1 ratio. Analgesia was maintained with fentanyl 1Âµg/kg/hr. Mannitol
      and sodium bicarbonate was given immediately before reperfusion (de-clamping of renal
      artery). Intraoperative monitoring included heart rate, noninvasive blood pressure, oxygen
      saturation, ETCO2, ECG and central venous line was placed in the right or left internal
      jugular vein depending upon the presence of dialysis catheter. Hemodynamic target include:
      mean arterial pressure of &gt; 80mmHg, CVP between 10-15 mm Hg to optimize cardiac output and
      renal blood flow.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum fluoride</measure>
    <time_frame>baseline before anesthesia</time_frame>
    <description>Serum inorganic fluoride</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum fluoride</measure>
    <time_frame>one hour postoperative</time_frame>
    <description>Serum inorganic fluoride</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum fluoride</measure>
    <time_frame>6 hours postoperative</time_frame>
    <description>Serum inorganic fluoride</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum fluoride</measure>
    <time_frame>12 hours postoperative</time_frame>
    <description>Serum inorganic fluoride</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum fluoride</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>Serum inorganic fluoride</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum fluoride</measure>
    <time_frame>48 hours postoperative</time_frame>
    <description>Serum inorganic fluoride</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>Baseline preoperative</time_frame>
    <description>kidney function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>kidney function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>48 hours postoperative</time_frame>
    <description>kidney function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>one week postoperative</time_frame>
    <description>kidney function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinine clearance</measure>
    <time_frame>baseline before anesthesia</time_frame>
    <description>kidney function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinine clearance</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>kidney function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinine clearance</measure>
    <time_frame>48 hours postoperative</time_frame>
    <description>kidney function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinine clearance</measure>
    <time_frame>one week postoperative</time_frame>
    <description>kidney function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine output</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>kidney function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine output</measure>
    <time_frame>48hours postoperative</time_frame>
    <description>kidney function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Kidney Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>anesthesia was maintained with Sevoflurane 1-2%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>isoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>anesthesia was maintained with isoflurane 1-2%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>anesthesia was maintained with Sevoflurane 1-2%.</description>
    <arm_group_label>Sevoflurane</arm_group_label>
    <other_name>Inhalational anesthetic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoflurane</intervention_name>
    <description>anesthesia was maintained with isoflurane 1-2%.</description>
    <arm_group_label>isoflurane</arm_group_label>
    <other_name>Inhalational anesthetic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  end stage renal disease

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdelrady S Ibrahim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>assiut university faculty of medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut university faculty of medicine</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Burchardi H, Kaczmarczyk G. The effect of anaesthesia on renal function. Eur J Anaesthesiol. 1994 May;11(3):163-8. Review.</citation>
    <PMID>8050420</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Abdelrady S Ibrahim, MD</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Isoflurane</mesh_term>
    <mesh_term>Anesthetics, Inhalation</mesh_term>
    <mesh_term>Fluorides</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

